NICE's Chairman Sir Michael Rawlins likes the new GSK CEO.
Drugmakers will have to remodel themselves “and the wise ones know that”, he told PharmaTimes.
He cited the efforts of Andrew Witty, chief executive of GlaxoSmithKline and “a man for whom I have an enormous amount of regard and respect” who is refocusing his business in a different way from the traditional model and good luck to him, I hope he succeeds”.
Sir Michael concluded by saying “we need a strong pharmaceutical industry to produce new drugs but it has to be at an affordable cost”.
More
Drugmakers will have to remodel themselves “and the wise ones know that”, he told PharmaTimes.
He cited the efforts of Andrew Witty, chief executive of GlaxoSmithKline and “a man for whom I have an enormous amount of regard and respect” who is refocusing his business in a different way from the traditional model and good luck to him, I hope he succeeds”.
Sir Michael concluded by saying “we need a strong pharmaceutical industry to produce new drugs but it has to be at an affordable cost”.
More
No comments:
Post a Comment